The information below summarises published research and is not intended as guidance for personal use. Mentions of brand or product names are for identification only and do not constitute endorsement.
The FDA has stepped up enforcement against pharmacies and outsourcing facilities producing compounded versions of semaglutide, the active ingredient in Wegovy and Ozempic. In recent months, the agency has issued warning letters to multiple entities, citing violations of current good manufacturing practice (CGMP) requirements and misbranding. These actions follow a surge in demand for the drug, which has been in shortage since 2022, leading many patients to seek alternatives from compounding pharmacies and online peptide sellers.
Compounded semaglutide is not FDA-approved, and the agency has long expressed concerns about quality, sterility, and potency. A 2023 analysis published in JAMA Network Open (PubMed) found that some compounded semaglutide samples contained impurities and inconsistent levels of the active ingredient. The FDA's latest warning letters highlight similar issues, including inadequate sterility testing and the use of non-pharmaceutical-grade ingredients. While compounding is legal under certain conditions, the agency maintains that mass production of semaglutide copies crosses the line into unlawful manufacturing.
Why Compounded Semaglutide Is Under Scrutiny
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. The FDA-approved versions are manufactured under strict CGMP standards. Compounded versions, however, often use semaglutide sodium or semaglutide acetate, which are not the same as the base form found in approved products. The FDA has stated that these salt forms are not supported by the same evidence of safety and effectiveness. A review in Diabetes, Obesity and Metabolism (PubMed) noted that the pharmacokinetics of different semaglutide salts have not been well studied in humans.
Compounding pharmacies argue that they are filling a gap left by persistent shortages. The FDA's drug shortage database currently lists Wegovy and Ozempic as in shortage, which legally permits compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. However, the agency has clarified that compounding semaglutide in bulk, or using non-shortage-designated salt forms, may violate the law. The recent enforcement actions target facilities that the FDA says are operating more like drug manufacturers than traditional compounding pharmacies.
The Online Peptide Marketplace Reacts
Online platforms selling research peptides have long offered semaglutide and related compounds such as retatrutide, a triple agonist still in clinical trials. These sellers often label their products "for research purposes only" and disclaim any intent for human use. Yet consumer demand has driven a thriving gray market. A 2024 study in JAMA (PubMed) reported that 42% of online peptide vendors surveyed sold GLP-1 receptor agonists without requiring a prescription. The FDA's crackdown on compounding may push more buyers toward these unregulated sources, increasing risks of contamination, incorrect dosing, and adverse events.
Retatrutide, which targets GLP-1, GIP, and glucagon receptors, has shown promising weight loss results in phase 2 trials, with participants losing up to 24% of body weight over 48 weeks (n=338). Despite lacking FDA approval, it is widely available from online peptide sellers. The FDA has not yet issued specific guidance on retatrutide compounding, but its inclusion in enforcement actions seems likely as demand grows. Other peptides like MOTS-c, PT-141, ipamorelin, and pinealon are also sold online, often with minimal quality control. A 2022 review in Trends in Endocrinology & Metabolism (PubMed) cautioned that the long-term safety of many mitochondrial-derived peptides, including MOTS-c, remains unknown.
What the Enforcement Means for Buyers
For individuals purchasing semaglutide or other peptides online, the FDA's actions signal heightened risk. The agency has not only targeted compounders but also issued import alerts and seized shipments of unapproved drugs. Buyers may face legal consequences if they import prescription-only substances without a valid prescription. More immediately, they risk receiving products that are mislabeled, contaminated, or subpotent. The FDA's MedWatch program has received reports of adverse events linked to compounded semaglutide, including hypoglycemia and injection-site reactions.
Some online communities have shifted to discussing peptides like ipamorelin, a growth hormone secretagogue, as alternatives. However, ipamorelin is not FDA-approved for any indication, and its long-term effects are poorly understood. A small study in Clinical Endocrinology (PubMed) found that ipamorelin increased growth hormone levels but noted that safety data beyond 12 weeks were lacking. Similarly, PT-141 (bremelanotide) is approved for hypoactive sexual desire disorder in premenopausal women, but its off-label use for sexual enhancement in other populations has not been rigorously studied. The FDA has warned against purchasing unapproved versions of these peptides.
Regulatory Gaps and Future Outlook
The FDA faces a difficult balancing act. Shortages of approved GLP-1 drugs are expected to persist through 2024, according to the agency's own projections. This leaves patients and prescribers in a bind. Some states have taken action independently, with boards of pharmacy issuing their own warnings or restrictions on compounded semaglutide. Meanwhile, the Alliance for Pharmacy Compounding has sued the FDA, arguing that the agency overstepped its authority in declaring certain semaglutide salt forms ineligible for compounding. A ruling in that case could reshape the landscape.
Looking ahead, the FDA is likely to continue targeting large-scale compounders and online sellers that make explicit health claims. The agency's recent reorganization of its compounding oversight program suggests a more proactive approach. For consumers, the safest course remains obtaining semaglutide through a licensed pharmacy with a valid prescription. Those who turn to online peptide sellers should be aware that the products they receive may not meet any recognized quality standards. As one FDA official noted in a recent webinar, "If it seems too good to be true, it probably is."
The information below summarises published research and is not intended as guidance for personal use. Mentions of brand or product names are for identification only and do not constitute endorsement.